Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
If anyone thinks iAbra is likely to be a threat with its Covid test, they should be aware that up to March 2019 it was a loss making company with a balance sheet that appeared insolvent to the extent of £70,294. It appears to be a very small relatively trivial company. Hardly any comparison with ACVT.
While Neil was at Autolus, he played a key role in their listing on NASDAQ.
This is VERY significant and can’t come soon enough for Avacta (a NASDAQ listing) so that it’s true value can be established far above what it is at present.
I wouldn’t mind betting North Atlantic Smaller Companies has picked em up!!
Looks like my prediction is coming good. Strong price performance on Friday has been followed through today - this one is going to move quite a lot higher.
I may be jumping the gun, but the price consolidation over the last few months looks to be drawing to a conclusion. A clear break above 28p or thereabouts would signal a clear path towards 60p.
I am getting in early.
This is really significant. The previous Woodford holding has now been cleared out and we now have a very aggressive US NASDAQ quoted company as a significant shareholder. Just look at their website https://acaciaresearch.com/
I would hate to be short of ORPH tomorrow morning. Fireworks ahead, i think.
Apparently it is a PCR test, so still needs a lab and/or kit
hTtps://covid.chronomics.com/buy therefore not comparable to Avacta's POC test.
Page 22 of today's paper - HMG in talks with Chronomics about a saliva test with a turnaround time from a lab of 'as short as an hour'.
What a joke - hasn't anyone within PHE heard of Avacta and what it is doing or is it the case that Avacta cannot be bothered coping with NHS bureaucracy? Hopefully, it is not the case that the Avacta POC test has failed which seems very unlikely given last week's news.
There is a free webinar at 3pm today at which one of Ergomed's experts will be talking about Covid-19, see
https://www.bigmarker.com/bioalliance-video-network/Ergomed-2020-05-263-2020-05-26-09-00-am?bmid=5ed921c22e7f
Really impressive stuff from Myles McNulty that everyone should read very carefully. It should remove any doubt about the potential of Avacta to be a very major company.
https://aimchaos.files.wordpress.com/2020/05/avacta-group-update-ii-part-i.pdf
I think the reaction to the deal in some quarters has been silly. Anyone who has dealt with Amazon - if they are thought to be the preferred commercial partner - would know they screw you to the ground with their terms. This deal will be far better for Avacta and its shareholders.
The people behind Moderna are great operators: they built up Boohoo into a £4Bn company and know what they are doing on the internet.
Guys,
It goes without saying that you don't put in place a distribution agreement on this scale without a product to sell! Therefore it is only a matter of a short time before we get the really good news that the LFD has worked and had regulatory approval from the FDA etc.
Massive news!
proactive research has issued a very bullish and comprehensive note on ORPH today.
Have you got your maths a bit wrong here? If you are suggesting a payout of 4 Euros a share that would total just over a billion for 263 million shares!
Seriously, IF FOX nets 40 m Euros that would equate to 13.3p per share with the actual business there for NIL! Its a binary bet but still very much worth taking...........
Guys,
You might like to muse on this: there are 617 biotech/pharma stocks quoted on NASDAQ/NYSE excluding the mature ones which I count as those paying dividends. They have an average value of $1.66Bn each. For those with historical earnings, the PERs average 64 and for those with forecast PERs, the average is 45.
The directors of Avacta need to get a move on with a US listing before the company is taken over on the cheap!! Our market cap of £235m is ridiculous for this quality of company.